Results 81 to 90 of about 122,145 (339)

The peptide agonist-binding site of the glucagon-like peptide-1 (GLP-1) receptor based on site-directed mutagenesis and knowledge-based modelling [PDF]

, 2016
Glucagon-like peptide-1 (7–36)amide (GLP-1) plays a central role in regulating blood sugar levels and its receptor, GLP-1R, is a target for anti-diabetic agents such as the peptide agonist drugs exenatide and liraglutide.
Adelhorst, Al-Sabah, Baggio, Beinborn, Biasini, Chen, Chen, Cheng, Coopman, Dan Donnelly, DeFronzo, Di Paolo, Donnelly, Drucker, Hoang, Hollenstein, Inooka, Kieffer, Knudsen, Koole, Koole, Koole, López de Maturana, López de Maturana, Mann, Mann, Mayo, Miller, Monaghan, Moon, Parthier, Perret, Pioszak, Rachel L. Dods, Roberts, Rodrigues, Runge, Runge, Sanchez, Siu, Solano, Tibaduiza, Turton, Underwood, Vertongen, Vilardaga, Wettergren, Wootten, Xiao, Yang, Ørskov   +50 more
core   +1 more source

Exposure‐adjusted safety and efficacy of GLP‐I and GLP‐1/GIP receptor agonists compared with non‐GLP‐I for weight management and type 2 diabetes: Based on FDA medical and statistical reports of 34 280 safety and 36 312 efficacy subjects

British Journal of Clinical Pharmacology, EarlyView.
Aims This work aimed to contextualize glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) and glucose‐dependent insulinotropic polypeptide (GIP) receptor agonists safety and efficacy regarding weight management (WM); we analysed Food and Drug Administration (FDA) Medical Reviews to analyse 14 medications using patient‐exposure year normalization and ...
Aishwarya Prasad, Anshu Arora, Arun Arora, Jeena Vaid, Arif Khan   +4 more
wiley   +1 more source

Next generation GLP-1/GIP/glucagon triple agonists normalize body weight in obese mice

Molecular Metabolism, 2022
Objective: Pharmacological strategies that engage multiple mechanisms-of-action have demonstrated synergistic benefits for metabolic disease in preclinical models.
Patrick J. Knerr, Stephanie A. Mowery, Jonathan D. Douros, Bhavesh Premdjee, Karina Rahr Hjøllund, Yantao He, Ann Maria Kruse Hansen, Anette K. Olsen, Diego Perez-Tilve, Richard D. DiMarchi, Brian Finan   +10 more
doaj   +1 more source

Recent advances in vasoactive intestinal peptide physiology and pathophysiology: focus on the gastrointestinal system. [PDF]

, 2019
Vasoactive intestinal peptide (VIP), a gut peptide hormone originally reported as a vasodilator in 1970, has multiple physiological and pathological effects on development, growth, and the control of neuronal, epithelial, and endocrine cell functions ...
Akiba, Yasutada, Iwasaki, Mari, Kaunitz, Jonathan D   +2 more
core  

Cyclic AMP signalling in pancreatic islets [PDF]

, 2010
Cyclic 3'5'AMP (cAMP) is an important physiological amplifier of glucose-induced insulin secretion by the pancreatic islet β-cell, where it is formed by the activity of adenylyl cyclases, which are stimulated by glucose, through elevation in ...
Furman, Brian, Ong, Wee Kiat, Pyne, Nigel J.   +2 more
core   +1 more source

Active surveillance of drug safety in healthcare data: Sequential monitoring of bacterial and serious urinary tract infection risk in sodium‐glucose cotransporter 2 inhibitor users

British Journal of Clinical Pharmacology, EarlyView.
Abstract Introduction Active surveillance of adverse events using healthcare data is emerging as complementary to the monitoring of spontaneous reports and stand‐alone pharmacoepidemiologic studies. The risk of urinary tract infections (UTIs) was listed as a special warning for sodium‐glucose cotransporter‐2 inhibitors (SGLT2is) when marketed in Europe
Haoxin Le, Dilsad Simay Peker, Lukas Frederic Westphal, Nikolai Brun, Christine Erikstrup Hallgreen, Morten Andersen   +5 more
wiley   +1 more source

Multiple Factors Related to the Secretion of Glucagon-Like Peptide-1

International Journal of Endocrinology, 2015
The glucagon-like peptide-1 is secreted by intestinal L cells in response to nutrient ingestion. It regulates the secretion and sensitivity of insulin while suppressing glucagon secretion and decreasing postprandial glucose levels.
XingChun Wang, Huan Liu, Jiaqi Chen, Yan Li, Shen Qu   +4 more
doaj   +1 more source

Glucagon Receptor Signaling and Lipid Metabolism

Frontiers in Physiology, 2019
Glucagon is secreted from the pancreatic alpha cells upon hypoglycemia and stimulates hepatic glucose production. Type 2 diabetes is associated with dysregulated glucagon secretion, and increased glucagon concentrations contribute to the diabetic ...
Katrine D. Galsgaard, Katrine D. Galsgaard, Jens Pedersen, Jens Pedersen, Filip K. Knop, Filip K. Knop, Filip K. Knop, Jens J. Holst, Jens J. Holst, Nicolai J. Wewer Albrechtsen, Nicolai J. Wewer Albrechtsen, Nicolai J. Wewer Albrechtsen   +11 more
doaj   +1 more source

Incretin-based therapy for type 2 diabetes mellitus is promising for treating neurodegenerative diseases [PDF]

, 2016
Incretin hormones include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). Due to their promising action on insulinotropic secretion and improving insulin resistance (IR), incretin-based therapies have become a new ...
Holscher, Christian, Li, Lin, Li, Yanwei
core   +1 more source

Anti‐Obesity Pharmacotherapy and Emerging Multimodal Interventions for Obstructive Sleep Apnea

Chronic Diseases and Translational Medicine, EarlyView.
Cellular and molecular mechanisms of obesity‐related obstructive sleep apnea (OSA). ADMA: asymmetric dimethyrarginine, NLRP3: nucleotide‐binding domain, leucine‐rich repeat family, Pyrin domain containing 3, TLR: toll‐like receptors, IL‐1β: interleukin‐1β, IL‐6: interleukin‐6; LPS: lipopolysacharide, ROS: reactive oxygen species, TNF‐α.
Anish Preshy, Cornelius J. Fernandez, Mohammad Hamid Nedai, Joseph M. Pappachan   +3 more
wiley   +1 more source